Cargando…
Vaccine adjuvants: mechanisms and platforms
Adjuvants are indispensable components of vaccines. Despite being widely used in vaccines, their action mechanisms are not yet clear. With a greater understanding of the mechanisms by which the innate immune response controls the antigen-specific response, the adjuvants’ action mechanisms are beginn...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356842/ https://www.ncbi.nlm.nih.gov/pubmed/37468460 http://dx.doi.org/10.1038/s41392-023-01557-7 |
_version_ | 1785075364699045888 |
---|---|
author | Zhao, Tingmei Cai, Yulong Jiang, Yujie He, Xuemei Wei, Yuquan Yu, Yifan Tian, Xiaohe |
author_facet | Zhao, Tingmei Cai, Yulong Jiang, Yujie He, Xuemei Wei, Yuquan Yu, Yifan Tian, Xiaohe |
author_sort | Zhao, Tingmei |
collection | PubMed |
description | Adjuvants are indispensable components of vaccines. Despite being widely used in vaccines, their action mechanisms are not yet clear. With a greater understanding of the mechanisms by which the innate immune response controls the antigen-specific response, the adjuvants’ action mechanisms are beginning to be elucidated. Adjuvants can be categorized as immunostimulants and delivery systems. Immunostimulants are danger signal molecules that lead to the maturation and activation of antigen-presenting cells (APCs) by targeting Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs) to promote the production of antigen signals and co-stimulatory signals, which in turn enhance the adaptive immune responses. On the other hand, delivery systems are carrier materials that facilitate antigen presentation by prolonging the bioavailability of the loaded antigens, as well as targeting antigens to lymph nodes or APCs. The adjuvants’ action mechanisms are systematically summarized at the beginning of this review. This is followed by an introduction of the mechanisms, properties, and progress of classical vaccine adjuvants. Furthermore, since some of the adjuvants under investigation exhibit greater immune activation potency than classical adjuvants, which could compensate for the deficiencies of classical adjuvants, a summary of the adjuvant platforms under investigation is subsequently presented. Notably, we highlight the different action mechanisms and immunological properties of these adjuvant platforms, which will provide a wide range of options for the rational design of different vaccines. On this basis, this review points out the development prospects of vaccine adjuvants and the problems that should be paid attention to in the future. |
format | Online Article Text |
id | pubmed-10356842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-103568422023-07-21 Vaccine adjuvants: mechanisms and platforms Zhao, Tingmei Cai, Yulong Jiang, Yujie He, Xuemei Wei, Yuquan Yu, Yifan Tian, Xiaohe Signal Transduct Target Ther Review Article Adjuvants are indispensable components of vaccines. Despite being widely used in vaccines, their action mechanisms are not yet clear. With a greater understanding of the mechanisms by which the innate immune response controls the antigen-specific response, the adjuvants’ action mechanisms are beginning to be elucidated. Adjuvants can be categorized as immunostimulants and delivery systems. Immunostimulants are danger signal molecules that lead to the maturation and activation of antigen-presenting cells (APCs) by targeting Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs) to promote the production of antigen signals and co-stimulatory signals, which in turn enhance the adaptive immune responses. On the other hand, delivery systems are carrier materials that facilitate antigen presentation by prolonging the bioavailability of the loaded antigens, as well as targeting antigens to lymph nodes or APCs. The adjuvants’ action mechanisms are systematically summarized at the beginning of this review. This is followed by an introduction of the mechanisms, properties, and progress of classical vaccine adjuvants. Furthermore, since some of the adjuvants under investigation exhibit greater immune activation potency than classical adjuvants, which could compensate for the deficiencies of classical adjuvants, a summary of the adjuvant platforms under investigation is subsequently presented. Notably, we highlight the different action mechanisms and immunological properties of these adjuvant platforms, which will provide a wide range of options for the rational design of different vaccines. On this basis, this review points out the development prospects of vaccine adjuvants and the problems that should be paid attention to in the future. Nature Publishing Group UK 2023-07-19 /pmc/articles/PMC10356842/ /pubmed/37468460 http://dx.doi.org/10.1038/s41392-023-01557-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Zhao, Tingmei Cai, Yulong Jiang, Yujie He, Xuemei Wei, Yuquan Yu, Yifan Tian, Xiaohe Vaccine adjuvants: mechanisms and platforms |
title | Vaccine adjuvants: mechanisms and platforms |
title_full | Vaccine adjuvants: mechanisms and platforms |
title_fullStr | Vaccine adjuvants: mechanisms and platforms |
title_full_unstemmed | Vaccine adjuvants: mechanisms and platforms |
title_short | Vaccine adjuvants: mechanisms and platforms |
title_sort | vaccine adjuvants: mechanisms and platforms |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356842/ https://www.ncbi.nlm.nih.gov/pubmed/37468460 http://dx.doi.org/10.1038/s41392-023-01557-7 |
work_keys_str_mv | AT zhaotingmei vaccineadjuvantsmechanismsandplatforms AT caiyulong vaccineadjuvantsmechanismsandplatforms AT jiangyujie vaccineadjuvantsmechanismsandplatforms AT hexuemei vaccineadjuvantsmechanismsandplatforms AT weiyuquan vaccineadjuvantsmechanismsandplatforms AT yuyifan vaccineadjuvantsmechanismsandplatforms AT tianxiaohe vaccineadjuvantsmechanismsandplatforms |